Extracorporeal membrane oxygenation mitigates myocardial injury and improves survival in porcine model of ventricular fibrillation cardiac arrest

Bo Liu, Qiang Zhang, Yong Liang, Yun Zhang, Xiaoli Yuan, Jiyang Ling and Chunsheng Li*

Abstract

Introduction: Despite decades of improved strategy in conventional cardiopulmonary resuscitation (CCPR), survival rates of favorable neurological outcome after cardiac arrest (CA) remains poor. It is indicated that the survival rate of successful resuscitation of extracorporeal membrane oxygenation (ECMO) is superior to that of CCPR. But the effect of ECMO in heart is unclear. We aimed to investigate whether ECMO produces cardiac protection by ameliorating post-ischemia reperfusion myocardial injury and myocardial apoptosis.

Methods: After undergoing 8-min untreated ventricle fibrillation (VF) and 6-min basic life support, 20 male pigs were ultimately used in this study and randomly divided into two groups: CCPR group (n = 10) and extracorporeal CPR (ECPR) group (n = 10). Hemodynamics and blood samples were obtained at baseline and 1, 2, 4, and 6 h during resuscitation. The successfully resuscitated pigs were sacrificed at 6 h after return of spontaneous circulation (ROSC), and the hearts were removed and analyzed under electron microscopy, and immunohistochemistry, quantitative real-time polymerase chain reaction, and immunofluorescence staining assay were performed to evaluate myocardial injury and myocardial apoptosis.

Results: There were no significant differences at basic hemodynamic status between the two groups. The survival rate of ECPR was significantly higher than CCPR group (10/10 [100%] vs. 4/10 [40%], P = 0.04). Compared to CCPR group, ECPR group exhibited a better outcome in hemodynamic function. Cardiac function was significantly impaired after ROSC in both groups, but left ventricular ejection fraction (LVEF) was significantly elevated in ECPR group than CCPR group. The expression of myocardial injury biomarkers (CK-MB, cTNI, H-FABP), endothelial injury biomarker (sP-selectin), and cardiac function biomarker (BNP) were remarkably increased after ROSC in both groups, but low levels in ECPR group than in CCPR group. Cardiomyocytes injury was attenuated in ECPR group under transmission electron microscopy (TEM). Typical apoptotic nuclei of cardiomyocytes were significantly reduced and oxidative damage were attenuated in ECPR group.

Conclusions: During prolonged VF-induced CA, ECPR contributes to improving hemodynamics, attenuating myocardial ischemia-reperfusion injury, ameliorating myocardial ultra structure, improving cardiac function, and elevating survival rate by preventing oxidative damage, regulating energy metabolism, inhibiting cardiomyocyte apoptosis.

Keywords: Cardiac arrest, Extracorporeal cardiopulmonary resuscitation, Ischemia reperfusion injury, Apoptosis, Cardiac function, Survival
**Introduction**

Despite decades of improved strategy in conventional cardiopulmonary resuscitation (CCPR), survival rates of favorable neurological outcome after cardiac arrest (CA) remains poor [1–6]. The estimated survival rates to hospital discharge with good neurological recovery range from 7.4 to 13.5% for adults with in-hospital CA (IHCA) [2, 6] and 3.2 to 7.3% for those with out-of-hospital CA (OHCA) [1, 3], respectively. With the development of medical technology and advanced devices, extracorporeal CPR (ECPR) by veno-arterial extracorporeal membrane oxygenation (ECMO) is increasingly applied as a rescue therapy for patients resuscitated from CA, and exhibits a higher return of spontaneous circulation (ROSC), improves cardiac function and leads to a favorable neurologically intact survival to hospital discharge compared to CCPR [7–11]. As the target organ of CPR, the recovery of spontaneous beat and function of the heart are very crucial for successful resuscitation after CA. ECPR offers the blood reperfusion and oxygen supply of vital organs during CA and provides a key bridge and time span for therapy decision. However, ECMO in cardioprotection after CA is still lack of evidence. Therefore, this study was designed to investigate the underlying cardioprotection and its mechanism of ECPR in a porcine model of prolonged ventricular fibrillation (VF) CA. We hypothesized that ECPR could attenuate myocardial injury and endothelial damage of post-resuscitation, improve cardiac function, reduce the apoptosis of cardiomyocytes and increase short-term survival rate.

**Methods**

This study was approved by the Institutional Animal Care and Use Committee of the Capital Medical University and performed at the Beijing Chao-Yang Hospital Affiliated to the Capital Medical University. All protocols strictly conformed to the National Research Council’s 1996 Guide for the Care and Use of Laboratory Animals.

**Animal preparation**

Twenty male pigs aged 11–13 months, with a mean body weight of 35.13 ± 5.57 kg were applied in this study and randomly divided into two groups: CCPR group (treated with CCPR after CA, n = 10) and ECPR group (treated with ECMO after CA, n = 10). Animal preparation was described in Additional file 1.

**Establishment of ECMO**

A 14Fr Biomedicus venous drainage cannula (Medtronic Perfusion Systems, Minneapolis, MN, USA) was inserted into the left femoral artery, and another 12 Fr Biomedicus arterial cannula was advanced into the left internal jugular vein for ECMO. The VA-ECMO circuit was primed by heparinized normal saline (5.0 U/mL) to avoid clotting of the cannulas. The VA-ECMO was driven by a centrifugal pump (ROTAFLOW Console, Maquet) and the water-circulating heat exchanger (Heat-Cooler Unit HCU 30, Maquet) was placed at a temperature of 34°C. Pump speeds were place at a rate of 50 mL/kg/min at the beginning, and were adjusted to optimize flow and mean arterial blood pressure during ECPR. An initial 500 mL bolus of normal saline and colloidal fluid were infused intravenously, followed by continuous infusion of 200–500 mL/h to compensate for fluid loss.

**Experimental protocol**

Experimental protocol was described in Additional file 1. The detailed experimental protocol is showed in Fig. 1.

**Outcomes**

The primary outcome of successful resuscitation was ROSC, and the secondary endpoints were the successful weaning of ECMO and 6-h short-term survival. Successful weaning was defined as a stable mean aortic pressure (MAP) > 65 mmHg that could be maintained with no ECMO flow.

**Hemodynamic measurements**

Hemodynamic variables, including heart rate (HR), MAP, central venous pressure (CVP), CO, CPP using the Swan-Ganz catheter were continuously measured. CPP was defined as the difference between the diastolic aortic pressure and the diastolic right atrial pressure. CO was determined using thermodilution method by injections of 10 mL ice-cold saline, and the CO was calculated as the average value of three consecutive measurements. These parameters were measured at baseline before induction of the VF, and 1 h after ROSC (ROSC 1 h), ROSC 2 h, ROSC 4 h, and ROSC 6 h after ECPR and CCPR.

**Measurements of cardiac function by echocardiography**

Echocardiography was performed by an ultrasonic doctor who didn’t participate in the experiment, and measurements were taken at baseline and at ROSC 1, 2, 4, 6 h, respectively. A 2- or 4-chamber long-axis view was obtained using a Hewlett-Packard Sonos 2500 echocardiographic system (Hewlett-Packard, Andover, Mass) with a 5.5/7.5-Hz biplane Doppler transesophageal echocardiographic transducer and a 4-way flexure. Left ventricular end-systolic and end-diastolic volumes were calculated by the disk method (Acoustic Quantification Technology; Hewlett-Packard). These parameters were used to determine left ventricular ejection fraction (LVEF).
Sample collection
Blood samples were collected at regular time intervals (at baseline, 1, 2, 4, 6 h during resuscitation) from the right femoral artery for measurement of cardiac biomarkers, and were placed in heparinized sterile tubes and centrifuged at 3000 r/min for 10 min, and samples with visible hemolysis were discarded. Plasma was immediately separated and stored at −80 °C until analysis. Lactate levels were measured by arterial blood gases examined (GEM Premier 3000 blood gas analyzer, Instrumentation Laboratory, Lexington, MA). Myocardial cellular injury was determined with MB isoenzyme of creatine kinase (CK-MB, H197, Nanjing, Jiancheng Bioengineering Institute), cardiac troponin I (cTNI, E019, Nanjing Jiancheng Bioengineering Institute), and heart-type fatty acid-binding protein (H-FABP, Shanghai Renjie Biotechnology Company, Ltd). Cardiac function and myocardial endothelial dysfunction were determined with B-type natriuretic peptide (BNP, H166, Nanjing Jiancheng Bioengineering Institute) and sP-selectin (Shanghai Renjie Biotechnology Company, Ltd), respectively. Plasma concentrations of these biomarkers were determined with quantitative sandwich enzyme-linked immunosorbent assay (ELISA) using commercially available kits (R&D).

Harvest of heart tissue
After the animals were sacrificed at 6 h after ROSC, the hearts were excised, the right ventricle and both atria were removed, and the left ventricle were frozen rapidly by immersion in liquid N2 and were stored −80 °C until requirement of measurements for Na⁺-K⁺-ATPase enzyme activity, Ca²⁺-ATPase enzyme activity, superoxide dismutase (SOD), and malondialdehyde (MDA). Measurements of Na⁺-K⁺-ATPase, Ca²⁺-ATPase, SOD enzyme activity and MDA content were just previously described [12].

Immunofluorescence staining
Immunofluorescence staining was performed on the fixed cardiac tissue slides using a standard protocol with primary antibodies, including monoclonal anti-Bax, anti-Bcl-2 antibodies and anti-caspase-3 (Beijing Boao Biotechnology Company) at 1:10,000 dilution (Cell Signaling Technology; Danver, USA) and secondary horseradish peroxidase (HRP)-conjugated goat anti mouse antibody at 1:1000 dilution. The staining results were observed under an optical microscopy (CX41; Olympus, Tokyo, Japan).

Ultrastructural analysis
Some myocardial specimen preserved in 10% formaldehyde and 4% paraformaldehyde were dissected from the left ventricular free walls of porcine hearts and 8 um-thick slices were cut from each tissue block using a cryostat microtome. The ultra structural pathologic changes of the myocardium were observed using light microscopy and TEM (JEM-1010; JEOL, Tokyo, Japan). The pathologic data were assessed by pathologists blinded to the experimental groups.

Statistical analysis
All data were analyzed using SPSS 19.0 software (SPSS, Chicago, IL, USA). Continuous variables are expressed as mean ± SD. Student’s t-test was used for comparisons between ECPR and CCPR groups. Differences at different time points were assessed by repeated-measures analysis of variance (ANOVA), and P-values from post-hoc testing were corrected for multiple comparisons using the Bonferroni correction. Survival analysis was performed using the method of Kaplan and Meier, and comparisons between groups were made using the log-rank test. A two-tailed P-value <0.05 was considered statistically significant.
Results

Survival rates
Twenty animals were successfully resuscitated. In CCPR group, during the following 6-h observation after ROSC, two of ten piglets died at 1 h, another four animals died at 2 h after ROSC, respectively. However, all ten piglets survived in ECPR group after ROSC. There was a significantly higher survival rate in ECPR group by the end of the 6-h experiment period using the Kaplan-Meier survival curve ($P<0.05$) compared to CCPR group (10/10 [100%] vs. 4/10 [40%]) (Fig. 2).

Baseline status
Baseline characteristics of the ECPR and CCPR group animals are shown in Table 1. No significant differences were found in baseline weight, HR, CO, MAP, CVP, CPP, hemoglobin level, and lactate level between the two groups ($P>0.05$).

MAP, CO and CPP decreased the minimum, and HR increased the peak at the start-time point of ROSC (ROSC 0) between ECPR group and CCPR group. There were no significant differences in HR [181.0 ± 4.18 vs. 183.7 ± 5.38, $P = 0.32$], MAP [63.9 ± 2.92 vs. 65.6 ± 2.30, $P = 0.28$], CO [2.43 ± 0.07 vs. 2.42 ± 0.13, $P = 0.79$] and CPP [57.8 ± 2.97 vs. 57.4 ± 2.90, $P = 0.81$] between the two groups at ROSC 0. MAP, CO and CPP were significantly higher in ECPR group than in CCPR group at 1 h [MAP, 100.5 ± 4.28 vs. 72.25 ± 2.22; CO, 2.69 ± 0.05 vs. 2.52 ± 0.03; CPP, 82.2 ± 3.58 vs. 72.3 ± 2.75]; 2 h [MAP, 109.5 ± 5.31 vs. 89.5 ± 2.08; CO, 2.87 ± 0.09 vs. 2.68 ± 0.03; and CPP, 81.9 ± 3.54 vs. 79.2 ± 2.60] and 4 h [MAP, 117.2 ± 5.12 vs. 99.75 ± 4.50; CO, 3.11 ± 0.14 vs. 2.73 ± 0.03; CPP, 81.6 ± 2.46 vs. 78.2 ± 2.78] after ROSC, but were not significantly different between the two groups at 6 h after ROSC [MAP, 116.2 ± 5.07 vs. 110.75 ± 5.06, $P = 0.09$; CO, 3.20 ± 0.03 vs. 3.18 ± 0.04, $P = 0.45$; CPP, 82.3 ± 3.23 vs. 81.25 ± 4.35, $P = 0.62$] (Fig. 3b, c, d). However, heart rates were significantly lower at all time points during the 6 h after ROSC in ECPR group compared to CCPR group (Fig. 3a).

Left ventricle cardiac function evaluation by echocardiography
The dynamic changes of left ventricle ejection fraction (LVEF) over time are showed in Fig. 4. There were no statistical differences for LVEF at baseline between the two groups [61.4 ± 2.22 vs. 60.01 ± 3.40, $P = 0.29$]. LVEF decreased gradually with the incidence of VF, and reached a minimum at the initial time point of ROSC (ROSC 0) in both groups, and then increased significantly with time, verged on the value of baseline at 6 h after ROSC [ROSC 6, 63.5 ± 2.27 vs. 60.25 ± 0.96, $P = 0.02$]. Compared with CCPR group, LVEF were significantly higher in ECMO group at 1 h [43.5 ± 2.25 vs. 32.5 ± 2.08, $P = 0.001$], 2 h [52.3 ± 2.28 vs. 44.25 ± 2.71, $P = 0.001$] and 4 h [56.7 ± 1.64 vs. 52.25 ± 1.26, $P = 0.001$].

![Fig. 2 Kaplan-Meier survival curve. There was a significantly higher survival rate in ECPR group compared to CCPR group ($P<0.05$ by log-rank test)](image-url)
Serum biomarkers levels of myocardial injury and cardiac dysfunction

As showed in Fig. 5, there were no significant differences for the serum levels of cTNI [2.07 ± 0.08 vs. 2.04 ± 0.05, \( P = 0.24 \)]; CK-MB [140.76 ± 1.47 vs. 141.62 ± 1.96, \( P = 0.28 \)]; H-FABP [1.75 ± 0.03 vs. 1.78 ± 0.04, \( P = 0.06 \)] and BNP [5.15 ± 0.3 vs. 4.93 ± 0.24, \( P = 0.09 \)] at baseline and the initial time point of ROSC (ROSC 0) [cTNI, 2.22 ± 0.26 vs. 2.11 ± 0.04; CK-MB, 155.37 ± 4.87 vs. 153.58 ± 2.09; H-FABP, 1.88 ± 0.08 vs. 1.86 ± 0.05; and BNP, 5.48 ± 0.55 vs. 5.30 ± 0.16] between the two groups, and were progressively elevated throughout the study time points after ROSC, reached the peak at 6 h after ROSC, and the levels of cTNI, CK-MB, H-FABP, and BNP were markedly higher in CCPR group compared to ECPR group at 1 h [cTNI, 4.77 ± 0.19 vs. 6.50 ± 0.11; CK-MB, 178.74 ± 7.22 vs. 204.62 ± 0.90; H-FABP, 1.98 ± 0.05 vs. 2.20 ± 0.01; BNP, 12.92 ± 0.99 vs. 17.93 ± 0.60]; 2 h

Table 1. Baseline characteristics between ECPR and CCPR groups

| Variable          | ECPR (n = 10) | CCPR (n = 10) | \( P \)-value |
|-------------------|---------------|---------------|--------------|
| Weight (kg)       | 31.70 ± 2.06  | 31.90 ± 2.51  | 0.309        |
| HR (bpm)          | 122.80 ± 9.52 | 127.60 ± 11.06 | 0.312        |
| CO (ml/kg/min)    | 3.78 ± 0.21   | 3.76 ± 0.26   | 0.859        |
| MAP (mmHg)        | 115.80 ± 6.56 | 116.80 ± 3.52 | 0.322        |
| CVP (mmHg)        | 5.40 ± 0.97   | 5.50 ± 1.08   | 0.656        |
| CPP (mmHg)        | 81.80 ± 2.90  | 83.00 ± 4.50  | 0.487        |
| Hemoglobin (g/dL) | 10.94 ± 0.33  | 11.02 ± 0.41  | 0.345        |
| Lactate (mmol/L)  | 3.03 ± 0.18   | 2.99 ± 0.17   | 0.609        |

\( HR \) heart rate, \( CO \) cardiac output, \( MAP \) mean aortic pressure, \( CVP \) central venous pressure, \( CPP \) coronary perfusion pressure

Fig. 3. Hemodynamic parameters between ECPR and CCPR groups. HR: heart rate; MAP: mean aortic pressure; CO: cardiac output; CPP: coronary perfusion pressure; CCPR: conventional cardiopulmonary resuscitation; ECPR: extracorporeal cardiopulmonary resuscitation; ROSC: return of spontaneous circulation; The solid triangle indicates ECPR group; The solid square denotes CCPR group; The bar length represents the standard deviation. \(*P < 0.05\) vs. CCPR group
[cTNI, 13.70 ± 0.76 vs. 16.06 ± 0.62; CK-MB, 362.82 ± 8.48 vs. 402.95 ± 2.65; H-FABP, 2.11 ± 0.04 vs. 2.35 ± 0.04; BNP, 23.38 ± 0.36 vs. 18.73 ± 0.89], 4 h [cTNI, 21.80 ± 0.56 vs. 25.84 ± 0.47; CK-MB, 766.5 ± 20.10 vs. 842.10 ± 3.48; H-FABP, 2.32 ± 0.05 vs. 2.47 ± 0.04; BNP, 28.63 ± 0.36 vs. 23.18 ± 0.85] and 6 h after ROSC [cTNI, 40.74 ± 1.07 vs. 47.76 ± 0.43; CK-MB, 841.89 ± 3.54 vs. 949.87 ± 1.78; H-FABP, 2.43 ± 0.03 vs. 2.59 ± 0.02; BNP, 38.05 ± 0.15 vs. 34.42 ± 1.60] (ROSC 1, 2, 4, 6 h) (P < 0.05). The sP-selectin concentrations were increased gradually compared to the baseline values before ROSC in the two groups, reached the maximum at ROSC 0 [9.25 ± 0.34 vs. 9.3 ± 0.24] and then decreased with time extension, and reached the minimum at 6 h after ROSC [6.73 ± 0.22 vs. 5.5 ± 0.19]. However, the sP-selectin and lactate concentrations were significantly lower in ECPR group than in CCPR group at 1 h, 2 h, 4 h, and 6 h after ROSC (P < 0.05).

The content of MDA and activities of Na⁺-K⁺-ATPase, Ca²⁺-ATPase and SOD of left ventricle myocardium
The activities of Na⁺-K⁺-ATPase, Ca²⁺-ATPase and SOD of left ventricle myocardium were significantly higher in ECPR group than in CCPR group at 6 h after ROSC. At the same time, the myocardial MDA content was significantly decreased in ECPR group compared to CCPR group (P < 0.05; Table 2).

Cardiomyocyte apoptosis
Immunofluorescence staining assay was performed to evaluate cardiomyocyte apoptosis and apoptosis was decreased in ECPR groups compared to CCPR group. Furthermore, upregulation of BCL-2 and downregulation of Bax and cleaved caspase-3 expression were detected in ECPR group (Fig. 6).

Ultrastructural changes in cardiomyocytes
Animals were sacrificed after ROSC 6 h, ultramicrostructural changes of cardiomyocytes were observed under TEM. Myocardial fiber and intercalated disk were found to be markedly disordered, broken, or dissolved. Most of the mitochondria were seriously damaged, vacuolar degenerated, mitochondria cristae were vague, arranged irregularly, or disrupted in CCPR group (Fig. 7a, c). However, the morphologic structure of cardiomyocytes included partial nuclear chromatin condensation, crest fracture, and moderate edema in the mitochondria and sarcoplasmic reticula, only exhibiting slight intracellular damage in ECPR group (Fig. 7b, d).

Discussion
ECPR has been originally used as a therapeutic option during refractory CA since 1976. In the 2010 American Heart Association (AHA) guideline, ECPR has been recommended as an alternative option for patients who have a brief no-flow time and a reversible cause of CA [13]. As the most severe shock state, CA results in the whole-body ischemia-reperfusion, during which the delivery of oxygen and supply of blood are abruptly halted, and a large amount of metabolites are produced and hardly removed [14]. Although conventional CPR may partially reverse this process, CO achieved is still much less than normal [15]. It has been showed that the most important determinant of ROSC during CPR is myocardial blood flow, which is driven by CPP. CPP during CPR has been considered as a leading predictor of successful resuscitation [16, 17]. In our study, pigs that
underwent CA between CCPR and ECPR groups presented the significantly decreased MAP, CO, LVEF and CPP, suggesting the severe post-resuscitation myocardial dysfunction (PRMD) and myocardial ischemia. Although the etiology of PRMD is not clear, it is thought to be associated with cardiovascular ischemia/reperfusion injury (IRI), cardiovascular toxicity from excessive levels of inflammatory cytokine activation and catecholamines, and...
other contributing factors [18]. However, increased microcirculatory blood perfusion, improved cardiac function, reduced oxygen consume of heart, as evidenced by progressively increased MAP, CO, LVEF and lower HR after successful ROSC in ECPR group indicated that ECMO played an important role in the recovery of cardiac function. In addition, a rapid and stable increase for CPP during CPR also ameliorated the myocardial blood perfusion, accelerated the recovery of cardiac function compared to CCPR, which was in line with previous studies [19, 20].

Cardiac biomarkers play a crucial role in the prediction of the severity of myocardial injury, cardiac dysfunction and prognosis in the early stage of post-resuscitation. Currently, serum cTNI, CK-MB and BNP are the most commonly used and sensitive biomarker available for early myocardial injuries and cardiac function [21]. Heart-type fatty acid-binding protein (H-FABP) also has been reported to be an early sensitive predictor for myocardial injury and higher plasma H-FABP levels suggest further cardiac events and worse prognosis [22]. Now it is commonly accepted that endothelial dysfunction and inflammation are involved in the physiopathology of CA. It has been showed that P-selectin, as an inflammatory adhesion molecule, its soluble form sP-selectin levels were significantly increased in the early stage of CA [23, 24]. Our findings showed that the levels of cTNI, CK-MB, H-FABP, BNP and sP-selectin were significantly elevated in each group after ROSC, but the concentrations were significantly lower in ECPR group than in CCPR group during resuscitation, suggesting that myocardial injury and endothelial damage were unavoidable after resuscitation, and application of ECMO can attenuate the degree of myocardial injury and endothelial damage, further improve cardiac function. Additionally, further cardioprotection by ECMO was associated with the descendent myocardial loading, decreased myocardial work, and reduced exogenic myocardial impairment by chest compressions.

CA causes inadequate cellular oxygen utilization, and results in an increase of lactate level which reflects abnormal cellular function. Numerous studies have revealed an association between initial serum lactate levels and survival in CA, and reported serum lactate level was an independent prognostic factor of mortality and neurological outcome [5, 25–27]. Hayashida K et al. [28] showed that effective lactate reduction over the first 6 h of post-CA care was implicated in survival and good neurologic outcome independently of the initial lactate level. Oxidative stress plays an important role in the process of IRI. During the CA-associated reperfusion of ischemic myocardium, a large amount of oxygen free radicals (OFRs) overproduced can result in oxidative damage for myocardium. The preserved activity of SOD has capable of clearing OFRs, which displays strong cardioprotective effects [29, 30]. As an end product of lipid peroxidation, MDA gives rise to cellular damage and disruption of cell membranes when tissue antioxidants are exhausted [31]. Na⁺-K⁺-ATPase is an important mediator in the regulation of vasculature tone and contractility, and decreased Na⁺-K⁺-ATPase expression induces cardiomyocytes death, ultimately leading to myocardial dilation, cardiac dysfunction, and even heart failure (HF) [32]. Ca²⁺-ATPase plays the major contribution in cardiomyocyte calcium removal, and is a key regulator of IRI. Similarly, overexpression of Ca²⁺-ATPase preserves cardiac function following IRI, improves cardiac performance and limits cardiac hypertrophy and HF [33]. In our present study, in contrast to CCPR group, ECPR group demonstrated a relatively lower lactate level, MDA content and higher SOD content, Na⁺-K⁺-ATPase and Ca²⁺-ATPase expression during resuscitation, indicating that ECMO may effectively improve tissue perfusion, increase oxygen utility, ameliorate the

Table 2 The content of MDA and the activity of Na⁺-K⁺-ATPase, Ca²⁺-ATPase and SOD in left ventricle tissue at 6 h after ROSC

| Parameter       | ECPR (U) | CCPR (U) | P-value |
|-----------------|----------|----------|---------|
| SOD (U/mg)      | 14.00 ± 0.32 | 11.89 ± 0.55 | < 0.05  |
| MDA (umol/g)    | 15.55 ± 0.53 | 22.78 ± 0.78 | < 0.05  |
| Na⁺-K⁺-ATPase   | 5.8 ± 0.09  | 3.19 ± 0.11  | < 0.05  |
| Ca²⁺-ATPase     | 6.33 ± 0.06  | 4.97 ± 0.15  | < 0.05  |

Values are shown as mean ± SD; ECPR Extracorporeal cardiopulmonary resuscitation, CCPR Conventional cardiopulmonary resuscitation

**Fig. 6** Apoptosis detection in porcine at 6 h after successful resuscitation. Representative images of immunostaining of Bcl-2, bax, and cleaved caspase-3. CCPR: Conventional cardiopulmonary resuscitation; ECPR: Extracorporeal cardiopulmonary resuscitation
energy metabolism and reduce oxidative damage of myocardium, and attenuate post-ischemia reperfusion cardiac dysfunction.

Accumulating evidence demonstrate that myocardial ischemia reperfusion after ROSC may induce cardiomyocytes apoptosis [34–36]. Apoptosis results in the reduction of quantities of contractile cardiomyocytes, leading to the decrease of cardiac pump capability, consequently induce heart failure. Bcl-2 (B cell lymphoma gene-2) family plays important roles in the regulation of cardiomyocytes apoptosis. Bcl-2 is the most important antiapoptotic protein, and Bax (Bcl-2-associated protein X) is the most characteristic death-promoting member of the Bcl-2 family. Overexpression of Bcl-2 relative to Bax inhibits apoptosis, and conversely, promotes apoptosis [37]. A family of caspases is another key regulator of apoptotic signaling pathway. Caspase-3 is one of the executioner caspases and is responsible for apoptotic cell death, leading to internucleosomal DNA fragmentation [37]. Aside from contributing to cell death, caspase-3 activation promotes the progressive loss of contractile function in heart by facilitating the degradation of myofibrillar proteins, leading to HF [38]. The present findings demonstrated that ECPR can decrease myocardial apoptosis, as evidenced by upregulation of Bcl-2 in relative to Bax and caspase-3 expression compared to CCPR. In addition, less apoptotic cardiomyocyte were observed under treatment with ECMO. These data indicate that ECMO can reduce IRI-induced cardiomyocyte apoptosis, suggesting a key role of ECMO in post-resuscitation myocardial dysfunction. Furthermore, histologic findings further provided the evidence that ECMO can alleviate post-ischemia reperfusion myocardial injury. There a difference between the dosages of epinephrine used between the two groups. The cardioprotecive effect of ECMO in this study could also be driven by saving on cardiotoxic catecholamines.

**Limitations**

Our study has some limitations to merit consideration. First, only young healthy pigs without any discernible coexisting disease were used in the experiment, which cannot be compared with humans who suffered from severe disease. The study was performed in animal with healthy hearts. It remains unclear, how ECMO support works in the case of acutely reduced lv dysfunction and a vulnerable heart like ischemic myocardium with baseline elevated filling pressures. Here, ECMO might be even harmful and aggravate myocardial damage due to the burden of the increased afterload. Second, the mechanism how ECMO inhibit myocardial apoptosis is still unknown. Third, the time frame of our study was set at 6 h after ROSC, which may not be sufficient to detect
the changes of function and apoptosis of myocardial. Four, in our experiment, ECMO was implanted under controlled conditions before the induction of CA, but in real conditions, we may implant ECMO under ongoing CPR with risk of vascular complications which may lead to delay of ECMO support. Thus, further studies are required to address these limitations.

Conclusions

Based on these experimental findings, we conclude that ECPR after prolonged VF-induced CA improves hemodynamics, attenuates myocardial injury and endothelial damage after ischemia reperfusion, decreases oxidative damage, reduces cardiomyocyte apoptosis, ameliorates myocardial ultrastructure, improves cardiac function, and ultimately elevates the survival rate. This study provides a novel basic animal data for the cardioprotection of ECMO in prolonged VF-induced CA.

Acknowledgements

The authors thank Lianjun Zhao for his technical assistance.

Authors’ contributions

C-SL conceived this study, designed the trial and obtained research funding. BL, QZ, YL, J-YL, X-LY, and YZ conducted the trial and collected data. BL analyzed data, performed statistical analysis, drafted and revised the manuscript. C-SL takes responsibility for the paper as a whole. All authors read and approved the final manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81372025) and the 2015 Annual Special Cultivation and Development Project for the Technology Innovation Base of the Beijing Key Laboratory Cardiopulmonary Cerebral Resuscitation (No.Z151100001615056).

Competing interests

The authors declare they have no competing interests.

Received: 26 May 2019 Accepted: 1 August 2019
Published online: 28 August 2019

References

1. Albaeni A, Ed SM, Akiyumele B, et al. The association between post resuscitation hemoglobin level and survival with good neurological outcome following out of hospital cardiac arrest. Resuscitation. 2016;99:7–12.
2. Khra R, Chan PS, Donnino M, et al. Hospital variation in time to epinephrine for nonshockable in-hospital cardiac arrest. Circulation. 2016;134:2105–14.
3. Pearson DA, Darrell Nelson R, et al. Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: results from a statewide quality improvement initiative. Resuscitation. 2016;105:165–72.
4. Avali L, Maggioni E, Formica F, et al. Favorable survival of in-hospital compared to out-of-hospital refractory cardiac arrest patients treated with extracorporeal membrane oxygenation: an Italian tertiary care Centre experience. Resuscitation. 2012;83:579–83.
5. Debaty G, Babaz V, Durand M, et al. Prognostic factors for extracorporeal cardiopulmonary resuscitation recipients following out-of-hospital refractory cardiac arrest. A systematic review and meta-analysis. Resuscitation. 2017;112:1–10.
6. Radeschi G, Mina A, Berta G, et al. Incidence and outcome of in-hospital cardiac arrest in Italy: a multicentre observational study in the Piedmont region. Resuscitation. 2017;119:48–55.
7. Shin TG, Jo II, Sim MS, et al. Two-year survival and neurological outcome of in-hospital cardiac arrest patients rescued by extracorporeal cardiopulmonary resuscitation. Int J Cardiol. 2013;168:3424–30.
8. Mosca MS, Narotsky DL, et al. Duration of conventional cardiopulmonary resuscitation prior to extracorporeal cardiopulmonary resuscitation and survival among adult cardiac arrest patients. Perfusion. 2016;31:200–6.
9. Kim SJ, Jung JS, Park JH, et al. An optimal transition time to extracorporeal cardiopulmonary resuscitation for predicting good neurological outcome in patients with out-of-hospital cardiac arrest: a propensity-matched study. Crit Care. 2014;18:535.
10. Lin JW, Wang MJ, et al. Comparing the survival between extracorporeal rescue and conventional resuscitation in adult in-hospital cardiac arrests: propensity analysis of three-year data. Resuscitation. 2010;81:796–803.
11. Maekawa K, Tanno K, Hase M, et al. Extracorporeal cardiopulmonary resuscitation for patients with out-of-hospital cardiac arrest of cardiac origin: a propensity-matched study and predictor analysis. Crit Care Med. 2013;41:1186–96.
12. Ji XF, Yang L, Zhang MY, et al. Shen-fu injection attenuates postresuscitation myocardial dysfunction in a porcine model of cardiac arrest. Shock. 2011;35:530–6.
13. Travers AH, Rea TD, Bobrow BJ, et al. Part 4: CPR overview: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:5676–84.
14. Zhang Q, Yuan W, Wang G, et al. The protective effects of a phosphodiesterase 5 inhibitor, sildenafil, on postresuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis. Crit Care. 2014;18:641.
15. Carretero MJ, Fontanals J, Angusti M, et al. Monitoring in resuscitation: comparison of cardiac output measurement between pulmonary artery catheter and NICCO. Resuscitation. 2010;81:404–9.
16. Nair MY, Sutton RM, Fiess SH, et al. Blood pressure- and coronary perfusion pressure-targeted cardiopulmonary resuscitation improves 24-hour survival from ventricular fibrillation cardiac arrest. Crit Care Med. 2016;44:e1111–7.
17. Halperin HR, Lee K, Zivian M, et al. Outcomes from low versus high-flow cardiopulmonary resuscitation in a swine model of cardiac arrest. Am J Emerg Med. 2010;28:195–202.
18. enzter JC, Chonde MD, Desfulian C. Myocardial dysfunction and shock after cardiac arrest. Biomed Res Int. 2015;2015:314796.
19. Stub D, Byrne M, Pellegrino V, et al. Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in a swine model of refractory ischemic cardiac arrest. Heart Lung Circ. 2013;22:421–7.
20. Reynolds JC, Salcido DD, et al. Extracorporeal membrane oxygenation for predicting good neurological outcome in cardiopulmonary resuscitation recipients following out-of-hospital refractory cardiac arrest. Int J Cardiol. 2013;168:3424–30.
21. Yang M, Hu X, Lu X, et al. The effects of α- and β-adrenergic blocking agents on postresuscitation myocardial dysfunction and myocardial tissue injury in a rat model of cardiac arrest. Transl Res. 2015;165:589–98.
22. Ye XD, He Y, Wang S, et al. Heart-type fatty acid binding protein (HFABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. Acta Pharmacol Sin. 2018;39:1155–63.
23. Troelsen TT, Granfeldt A, Secher N, et al. Impaired NO-mediated vasodilation in rat coronary arteries after asphyxial cardiac arrest. Acta Anaesthesiol Scand. 2013;59:654–67.
24. Gando S, Nanzaki S, Morimoto T, et al. Alterations of soluble L- and P-selectins during cardiac arrest and CPR. Intensive Care Med. 1999;25:588–93.
25. Ienselychmid C, Kalt J, Gamp M, et al. Routine blood markers from different biological pathways improve early risk stratification in cardiac arrest patients: results from the prospective, observational COMMUNICATE study. Resuscitation. 2018;130:138–45.
26. Donnino MW, Andersen LW, Giberson T, et al. Initial lactate and lactate change in post-cardiac arrest: a multicenter validation study. Crit Care Med. 2014;42:1804–11.
27. Laurikkala J, Skrifvars MB, Bäcklund M, et al. Early lactate values after out-of-hospital cardiac arrest: associations with one-year outcome. Shock. 2019;51:168–73.
28. Hayashida K, Suzuki M, Yonemoto N, et al. Early lactate clearance is associated with improved outcomes in patients with Postcardiac arrest syndrome: a prospective, multicenter observational study (SOS-KANTO 2012 study). Crit Care Med. 2017;45:e559–66.
29. Chambers DJ, Braimbridge MV, Heerse DJ. Free radicals and cardioplegia. Free radical scavengers improve postischemic function of rat myocardium. Eur J Cardiothorac Surg. 1987;1:37–45.
30. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res. 2009;81:449–56.
31. Cohen MV. Free radicals in ischemic and reperfusion myocardial injury: is this the time for clinical trials? Ann Intern Med. 1989;111:918–31.
32. Liu C, Bai Y, Chen Y, et al. Reduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac dysfunction and myocyte apoptosis. J Biol Chem. 2012;287:16390–8.
33. Sadi AM, Afroze T, Siraj MA, et al. Cardiac-specific inducible overexpression of human plasma membrane Ca2+-ATPase 4b is cardioprotective and improves survival in mice following ischemic injury. Clin Sci (Lond). 2018;132:641–4.
34. Yeh CH, Chen TP, Wang YC, et al. Carvedilol treatment after myocardial infarct decreases cardiomyocytic apoptosis in the peri-infarct zone during cardioplegia-induced cardiac arrest. Shock. 2013;39:343–52.
35. Liang LN, Zhong X, Zhou Y, et al. Cardioprotective effect of nicorandil against myocardial injury following cardiac arrest in swine. Am J Emerg Med. 2017;35:1082–9.
36. Wang G, Zhang Q, Yuan W, et al. Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation. Int J Mol Med. 2016;38:1463–73.
37. Dorn GW 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. Cardiovasc Res. 2009;81:465–73.
38. Yang B, Ye D, Wang Y. Caspase-3 as a therapeutic target for heart failure. Expert Opin Ther Targets. 2013;17:255–63.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.